Hysteresis control of epithelial-mesenchymal transition dynamics conveys a distinct program with enhanced metastatic ability

Toni Celià-Terrassa1,7, Caleb Bastian2, Daniel D. Liu1, Brian Ell1, Nicole M. Aiello1, Yong Wei1, Jose Zamalloa1,3, Andres M. Blanco1, Xiang Hang1, Dmitriy Kunisky4, Wenyang Li1, Elizabeth D. Williams5, Herschel Rabitz2,6 & Yibin Kang1

Epithelial-mesenchymal transition (EMT) have been extensively characterized in development and cancer, and its dynamics have been modeled as a non-linear process. However, less is known about how such dynamics may affect its biological impact. Here, we use mathematical modeling and experimental analysis of the TGF-β-induced EMT to reveal a non-linear hysteretic response of E-cadherin repression tightly controlled by the strength of the miR-200s/ZEBs negative feedback loop. Hysteretic EMT conveys memory state, ensures rapid and robust cellular response and enables EMT to persist long after withdrawal of stimuli. Importantly, while both hysteretic and non-hysteretic EMT confer similar morphological changes and invasive potential of cancer cells, only hysteretic EMT enhances lung metastatic colonization efficiency. Cells that undergo hysteretic EMT differentially express subsets of stem cell and extracellular matrix related genes with significant clinical prognosis value. These findings illustrate distinct biological impact of EMT depending on the dynamics of the transition.
EMT is a cellular program that occurs in embryonic development, wound healing, fibrosis, and cancer, during which epithelial cells transdifferentiate into a mesenchymal cell fate. The conversion involves dramatic phenotypic changes: epithelial cells lose cell polarity and intercellular junctions, rearrange their cytoskeleton, and acquire motile and invasive properties. Importantly, the process is reversible through mesenchymal-epithelial transition (MET), which is essential when migratory cells arrive at their destination to form specific tissues of the embryo. EMT plasticity is also critical during cancer metastasis as it enables tumor cells to acquire the invasive properties necessary to escape the primary tumor and disseminate, extravasate to distant tissues, and subsequently revert back to the epithelial state to form overt metastases and colonize a secondary organ.

Besides invasion, EMT also endows tumor cells with additional properties, including stem cell-like traits, immune evasion, and chemoresistance. However, the requirement of EMT in metastasis has been suggested to be dispensable in some recent studies using genetically modified mouse models. It has also been shown that extreme EMT can suppress stem cell properties and reduce metastatic ability if not reverted. Thus, the role of epithelial-mesenchymal plasticity in cancer metastasis is more complicated than initially thought. Notably, many of the previous studies focused on characterizing the endpoint of EMT/MET, while little attention was given to how the cellular dynamics of EMT may have an impact on its metastasis-promoting effect.

The EMT gene program is regulated by a complex network of transcription factors, miRNAs, long non-coding RNAs, epigenetic modulators, and external microenvironmental signals. Ultimately, the pathways inducing EMT converge to suppress epithelial genes, such as E-cadherin, which is considered the hallmark molecule of the epithelial status. A potent inducer of EMT is TGF-β, which signals through the TGF-β receptor-Smad pathway to increase the expression of master transcriptional regulators of EMT such as SNAI1 and ZEB1, a zinc-finger transcriptional repressor of E-cadherin. In addition, ZEB1 represses the expression of the miR-200 family of miRNAs, which reciprocally repress ZEB1/2 and TGF-β production. The miR-200s/ZEBs negative feedback loop is known to maintain epithelial homeostasis when miR-200 level is high, and it is also the most influential feedback loop for sustaining the mesenchymal state when Zeb1/2 are highly expressed.

Interestingly, computational studies have indicated non-linear bistable EMT dynamics based on feedback loops at the core of the EMT regulatory network. In particular, the system possesses two accessible stable steady states of E-cadherin expression (Fig. 1b, left panel), but not in the altered, non-hysteresis model (Fig. 1b, right panel). In particular, the system possesses two accessible stable steady states of E-cadherin expression (Fig. 1b, left panel, black curves), which are separated by instability of intermediate expression (green curve). The forward orbits of the iterated function system for the ODE system reveal the two steady state attractors, epithelial or mesenchymal (Supplementary Fig. 1a). These suggest E-cadherin expression to experience dynamics of hysteresis control (also known as “bang bang” control). Simulated steady-state dynamics of a collection of homogeneous cells, represented by an ensemble of stochastic ODEs, shows a non-linear transition from high to low E-cadherin levels with increasing TGF-β input (Fig. 1c). Similarly, cell population simulation studies show a bimodal distribution of the transition regardless of whether TGF-β treatment is continuous or transient (pulsed input) (Fig. 1d). However, in a putative system without hysteresis, the transition dynamics are monotone and unimodal, gradually decreasing with increasing TGF-β input (Fig. 1c, d).

We experimentally validated these mathematical predictions using fluorescent-activated cell sorting (FACS) of fixed cells and immunofluorescence (IF) analyses in NMuMG mouse mammary epithelial cells and EpRAS mouse mammary tumor cells, which are classical models to study TGF-β-induced EMT. High dose (100 pM) of TGF-β treatment induced a shift in the entire population of cells from epithelial state (high E-cadherin) to the mesenchymal state (low E-cadherin) in a 3-day treatment experiment. A bimodal distribution of two distinct populations of cells with high and low level of E-cadherin expression existed within a certain range of TGF-β concentration (particularly between 10–30 pM) (Fig. 1e, f and Supplementary Fig. 1b, c).

Interestingly, 1-h transient treatment of TGF-β followed by TGF-βRI kinase inhibitor (LY2109761) to completely block TGF-β signaling was still sufficient to induce similar EMT shift and bimodal transition after 3 days (Fig. 1e, f and Supplementary Fig. 1b, c), indicating that these cells were able to undergo EMT upon a certain threshold of transient TGF-β exposure and have molecular memory. In addition, using a GFP reporter controlled by the E-cadherin (CDH1) promoter, we were able to observe the same dynamics of GFP expression, suggesting that the hysteresis control is at the transcriptional level (Supplementary Fig. 1d, e).

Finally, to explore the natural existence of different modes of EMT (hysterotic or non-hysterotic), we test the cellular dynamics of EMT in several normal or cancerous mammary epithelial cell lines from human or mouse. Interestingly, while most of the cell lines exhibited hysteresis in TGF-β-induced EMT, the BT474 human breast cancer cell line showed non-hysteretic, unimodal
Fig. 1 Mathematical modeling and experimental validation of mammary epithelial cells undergoing EMT. a Diagram of the simplified model of TGF-β induced EMT and the central role of the miR-200-Zeb double negative feedback loop. b Hysteresis within EMT and MET as indicated by CDH1 expression level (left panel) and altered model (non-hysteresis, right panel), based on ODE single cell deterministic model. Within a certain range of TGF-β (2.5-12 arbitrary unit), the steady-state CDH1 level is bistable and is either high or low, depending on the previous state of the cells (i.e. whether it is undergoing EMT or MET). c Simulated steady-state calculations of CDH1 level in a homogeneous collection of cells in increasing dose of TGF-β. Heatmap graphs depict CDH1 expression at single cell level (color indicates cell count for a given CDH1 expression level) and the dashed line represents CDH1 expression as the average of the population. Note the bistable shift in the hysteresis model (left) versus the gradual shift in the non-hysteresis model (right). d Computational simulation of CDH1 expression after different regimes of TGF-β treatment in a cell population. e Flow cytometry analysis and f Immunofluorescence of the endogenous CDH1 expression in parental NMuMG cells after treatment with indicated concentrations of TGF-β for 72 h (histograms, left), or for just 1 h of transient treatment, followed by measurement of CDH1 expression 72 h later (histograms, right). g Flow cytometry analysis of CDH1 expression in multiple normal and cancerous mammary epithelial cell lines after 100 pM TGF-β treatment for 9 days. Scale bar: 20 μm in f dynamics (Fig. 1g). This result suggests the existence of distinct modes of EMT dynamics in nature.

Hysteresis is controlled by the miR-200/Zeb1 feedback loop. To identify the molecular mechanism of hysteresis control in our system of study, we first generated independent random realizations of the model parameters on a scaled hypercube (reflecting maximum entropy). Then, for each random input vector, we estimated a measure of hysteresis extent. The empirical probability density and cumulative distribution functions revealed hysteresis extent to be bimodal, conveying the hysteresis bifurcation (Supplementary Fig. 2a). Then, we used high dimensional model representation (HDMR) to identify the hierarchy of independent and cooperative functional molecular effects, known as HDMR component functions, to elucidate how the model parameters functionally convey hysteresis;32,33 the structure of the HDMR component functions additionally conveys a global sensitivity analysis (GSA). From the random input-output data, we estimated first- and second-order HDMR component functions and their sensitivity indices. Through this analysis, we discovered key system parameters to underlie hysteresis: (kZ) reaction coefficient of TGF-β induction of Zeb; (kZ') Michaelis–Menten constant of Zeb binding and transcriptional repression of the miR-200s promoter; (kZ') reaction coefficient of miR-200s binding and post-transcriptional repression of Zeb; and...
Michaelis–Menten constant of Zeb binding to and transcriptional repression of the E-cadherin promoter (Fig. 2a, and Supplementary Table 4). The analyses revealed that the strongest contributor to hysteresis is $K_Z'$, suggesting the direct repressive action by Zebs on the miR-200s promoter to be critical. Moreover, the $K_Z'$ component function is highly non-linear, with significant contribution to hysteresis only occurring for small values of $K_Z'$, which correspond to its repressive action ability (Fig. 2b, left panel). Importantly, the second-order HDMR analysis suggests that a small increase on $K_Z'$ values eliminates hysteresis of the system by increasing low fidelity repressive action (Fig. 2b, right panel).

To experimentally prove this prediction, we used the CRISPR/Cas9 system to edit the ZEB1 binding sites on the endogenous promoter of miR-200s in NMuMG and EpRAS cells. In particular, we eliminated the Z-box-2 binding site (CAGGTA)
on the promoter of cluster-2 miRNAs (miR-200c/miR-141) of the miR-200 family, located on the murine chromosome 6 (Fig. 2c). This binding site is the most conserved Zeb binding site between wild type cells and has been shown to confer the strongest repressive function.16 Moreover, it is exclusive for ZEB1 of miR-200c/miR-141. As expected, TGF-β treatment reduced cluster-1 (miR-200a/miR-200b/miR-429), but did not reduce cluster-2 (miR-200c/miR-141) levels in the generated mutant cells, unlike the strong suppression of miR-200s by ZEB1 in wild type cells (Supplementary Fig. 2b), indicating that mutation of Z-box-2 was sufficient to impair the negative regulation of ZEB1 of miR-200c/miR-141. As expected, TGF-β treatment reduced cluster-1 (miR-200a/miR-200b/miR-429), but did not reduce cluster-2 (miR-200c/miR-141) levels in mutant cells (Fig. 2e), and consequently the increase of Zeb1/2 expression levels was slightly weaker compared to wild type cells (Supplementary Fig. 2c). Likewise, in BT474 cells that did not display hysteresis (Fig. 1g), there is a lack of miR-200c down-regulation upon ZEB1-OE and TGF-β treatment (Supplementary Fig. 2d). Importantly, despite the mentioned changes and slightly higher basal levels of miR-200s in mutant cells (Fig. 2e), we observed that NMuMG and EpRAS mutant cells still underwent EMT upon continuous TGF-β induction to a similar degree as their wild type counterparts based on analysis of EMT marker expression (Fig. 2d and Supplementary Fig. 2e). This result suggests that our precise genomic manipulation of the miR-200c promoter can subtly alter the natural balance of the miR-200s/ZEBs axis without preventing cells from undergoing EMT. It is also important to note that in this model of EMT induced by 100 pM TGF-β, none of the cells reached an extreme EMT state, as seen by some residual expression of E-cadherin shown by western blot analysis (Fig. 2d and Supplementary Fig. 2e).

Finally, we analyzed the EMT dynamics by monitoring E-cadherin expression of different wild type and mutant clonal populations using FACS and IF. In response to treatment using increasing concentrations of TGF-β, both NMuMG-AZ-box-2 and EpRAS-AZ-box-2 (hereafter referred as mutant cells) showed a unimodal gradual transition to a mesenchymal state (Fig. 2f, g and Supplementary Fig. 2f), in contrast to the bimodal transitions observed in their wild type counterpart. We consistently observed the same phenomenon in multiple wild type and mutant clones of NMuMG cells (Supplementary Fig. 2g), indicating that the change in EMT dynamics is due to the specific Z-box mutation rather than clonal variations. Therefore, disruption of the Zeb/miR-200 feedback loop led to the loss of bistability (hysteresis) in EMT, and turned it into a gradual linear transition (non-hysteresis). These results confirmed the predictions by HDMR and demonstrated that a modest disturbance of the miR-200s/ZEB1 double-negative feedback loop disrupts the hysteresis bifurcation and dramatically alters the cellular dynamics of EMT.

Hysteresis sets the threshold and persistence of EMT. To further analyze the temporal kinetic differences of hysteretic and non-hysteretic EMT, which might have relevant physiological importance, we characterized different induction times and steady states using the wild type (hysteresis) and mutant (non-hysteresis) cells. While both wild type and mutant NMuMG cells switched off E-cadherin expression after 2 days of continuous TGF-β (100 pM) treatment, more than 60% of wild type population had already completed the transition after 24 h (Fig. 3a). Instead, the mutant cells still displayed medium E-cadherin levels at 24 h. We next interrogated the minimal exposure time of TGF-β required to induce EMT after 3 days of treatment. Interestingly, a 5-min pulse of TGF-β treatment was enough to induce EMT in the entire population of wild type cells, while non-hysteretic mutant cells required at least 1 h of TGF-β treatment to undergo EMT, as measured by FACS of E-cadherin (Fig. 3b). We did not observe significant difference in SMAD2/3 phosphorylation between wild type and mutant cells upon TGF-β treatment (Supplementary Fig. 3a) despite a slight decrease of endogenous TGF-β1 mRNA levels in mutant cells ( Supplementary Fig. 3b), suggesting that the difference in EMT is unlikely to be due to variation in TGF-β signaling strength. In agreement with the FACS result (Fig. 3b), the time course analysis of EMT marker genes demonstrated that only hysteresis EMT in wild type cells can engage the EMT gene program with only 5-min short pulse of TGF-β treatment (Fig. 3c). Of note, Zeb1 induction and Cdh1 downregulation preceded Snail induction and other changes of EMT markers (Cdh2, Vim, Fn1), suggesting Zeb1 as the initial driving factor of hysteretic EMT. In contrast, such EMT-related gene expression changes are lacking or at least are not sustained in mutant cells. Consistently, while continuous TGF-β treatment was able to suppress cluster-1 miR-200 (such as miR-200b) expression in mutant cells, 5 min pulsed TGF-β treatment was not able to do so (Supplementary Fig. 3c). These differences highlight the importance of hysteresis in EMT response to short term exposure to TGF-β. Importantly, 5 min short pulse of TGF-β treatment in wild type EpRAS cells was enough to increase lung metastasis similar to that of the continuous TGF-β treatment (Fig. 3d), which highlights the functional and physiological importance of the EMT dynamics.

Our mathematical model predicted a bidirectional effect of EMT-MET hysteresis as reflected by the re-acquisition of E-cadherin expression with the removal of TGF-β (Fig. 3e). To examine the spatiotemporal dynamics of hysteresis vs non-hysteresis EMT, we mathematically modeled the persistence of EMT and MET reversion to the epithelial state by incorporating autocrine dynamics into the core model and by equipping the TGF-β field with diffusion, organizing cells into a 2D periodic array (Fig. 3e). We simulated and predicted that a cell population in the mesenchymal-like state has a time-extended mesenchymal persistence by hysteresis, whereas without hysteresis the system displays an earlier gradual reversion (Fig. 3f and Supplementary Table 5). To experimentally validate the mathematical prediction of hysteresis during MET, we first treated the NMuMG and EpRAS cells for 3 days with different concentrations of TGF-β to reach the mesenchymal state in both wild type and mutant cells, and then withdrew TGF-β and measured E-cadherin by FACS in the following days. Consistent with mathematical prediction, E-cadherin kinetics showed that the wild type cells followed bimodal reversion which was completed after 12-15 days, whereas the mutant cells reversed to the epithelial phenotype in a linear gradual mode within 4-5 days after TGF-β withdrawal (Fig. 3g and Supplementary Fig. 3d, e). This result showed that MET also follows hysteresis and maintains extended mesenchymal state in wild type cells, while the mutant cells follow a linear and accelerated MET.
Fig. 3 Dynamic analysis of the hysteretic and non-hysteretic EMT in NMuMG and EpRAS cells. 

a. Analysis of the dynamic of EMT induction (100 pM TGF-β) in wild type and mutant NMuMG cells by flow cytometry analysis of CDH1. The time represents the duration of treatment at the moment of measurement. 

b. Minimum exposure time of 100 pM TGF-β required to induce EMT in wild type and mutant NMuMG cells by flow cytometry analysis of CDH1. The time represents the duration of the transient treatment, with the measurement done 72 h post-induction for all conditions. 

c. Quantification of lung metastatic nodules and bioluminescence imaging (BLI) quantification of the metastatic growth of wild type EpRAS cells in the lungs after tail vein (T.V.) injection of 20,000 cells in Ncr-nu/nu mice (n = 3 technical replicates).

d. Simulation of EMT reversion in mesenchymal-like cell populations by modeling CDH1 expression with or without hysteresis. Red represents the epithelial cells (CDH1-high) and blue the mesenchymal cells (CDH1-low). 

e. Analysis of the hysteretic and non-hysteretic EMT in NMuMG and EpRAS cells. 

f. Flow cytometry analysis of CDH1 expression showing the reversion kinetics in wild type versus mutant NMuMG cells. Cells were treated with indicated concentration of TGF-β for 72 h, after which TGF-β was withdrawn and cells allowed to revert for indicated duration. Data represent mean±SEM in c and d. *P < 0.05, **P < 0.01, ***P < 0.005 by two-tailed Student’s t-test in c and d.
was weakened with mild gradual decrease of E-cadherin (Fig. 4b and Supplementary Table 6). This is consistent with the lack of molecular memory of linear systems and the notion that the mesenchymal state is buffered by the autocrine induction of the miR-200s/ZEBs axis. To experimentally prove these predictions, we performed cell co-culture assays. We first induced EMT in NMuMG-GFP cells by TGF-β treatment. 24 h later, unlabeled cells were added for co-culture and analyzed 72 h later by immunofluorescence analysis of CDH1. EMT-induced NMuMG-GFP cells instigated EMT in untreated NMuMG cells, leaving behind few patches of epithelial cells, whereas the mutant cultures were not able to spread the signal efficiently and only mild inductions are observed in a diffusive fashion (Fig. 4c, d, right panel and Supplementary Fig. 4b). Notable, several TGF-β-induced pro-metastatic genes, such as Angptl4, Jag1, Mmp9, and Vegfa were induced in the wild type NMuMG cells, likely by the paracrine TGF-β spreading effect during co-culture, but not in the mutants due to their inability to undergo EMT by the spread effect (Supplementary Fig. 4c). Accordingly, untreated wild type EpRAS cells had significant increase in lung metastasis ability in vivo when they are in co-cultured with EMT-like cells (Fig. 4e, f). Overall, these results demonstrate the impact of hysteresis EMT at the populational level, with functional importance in promoting metastatic competency of neighboring cells.

**Non-linear hysteresis EMT dynamics increases metastasis.** We next investigated whether the different modes of EMT (hysteretic vs non-hysteretic) have any impact on the functional properties of the cells. In vitro invasion assays showed a similar gain of
invasive ability in both wild type and mutant EpRAS and NMuMG cells after TGF-β induced EMT (Fig. 5a and Supplementary Fig. 5a), which was expected based on the similar degree of EMT markers expression changes (Fig. 2d and Supplementary Fig. 2e) and cell morphology (Supplementary Fig. 5b). In contrast, tumorsphere formation assays in vitro showed increased sphere-forming ability in wild type cells undergoing hysteretic EMT but not in mutant cells (Fig. 5b). In vivo mammary fat pad limiting-dilution injections demonstrated a significant increase in tumor-initiating cell (TIC) frequency in TGF-β-induced wild type EpRAS cells compared to mutant cells (Supplementary Fig. 5c).

We next performed tail vein injections to test lung metastatic colonization. Importantly, wild type EpRAS cells, but not mutant cells, had higher ability to form lung metastasis than mutant cells after TGF-β-induced EMT (Fig. 5c, d). Immunofluorescence and confocal microscopy analysis of the metastatic tissues after 19 and 28 days showed the same degree of tumor re-epithelization of E-cadherin expression in both systems over the time, including non-treated control cells (Fig. 5e), indicating that the increase in metastasis is not due to extended maintenance of the EMT-like phenotype during metastatic formation. Overall, these results demonstrated that hysteretic EMT induces tumor initiation and pro-metastatic properties much more prominently than non-hysteretic EMT, highlighting the previously unknown importance of the EMT dynamics in the pathological behavior of cancer cells during metastasis initiation.

Based on these results, we hypothesized that changes in the dynamics of EMT may cause an alteration of the associated EMT gene programs and cellular features related to metastatic ability. Therefore, we performed mRNA transcriptomic profiling, comparing wild type and mutant EpRAS cells after 3 days of 100 pM TGF-β treatment when all cells have reached EMT in both wild type and mutant EpRAS cells. Gene set enrichment analysis (GSEA) revealed a high number of genes differentially expressed between wild type and mutant EpRAS cells after TGF-β-induced EMT. A total of 2413 genes were differentially expressed (FC > 2) among the wild type and mutant cells. Despite no major changes in the degree of enrichment of the EMT_HALLMARK genes between wild type and mutant cells (Supplementary Fig. 5d), as expected, a subset of 22 miR-200 target genes were uniquely upregulated in the TGF-β treated wild type cells and not in mutant cells (Supplementary Fig. 5e), presumably due to the inability of TGF-β treatment to decrease cluster-2 miR-200 levels in the mutant cells (Fig. 2e). Interestingly, the mammary stem cell gene set (Lim_MaSCs) and the ECM (Naba_ECM_GLYCOPROTEINS) were more strongly enriched by the hysteretic EMT (Fig. 5f), with 33 and 22 genes upregulated by >1.95 fold by hysteretic-EMT, respectively (Fig. 5f). Many of these genes are related to stem cells properties and ECM proteins, which are two important features associated with increased metastatic colonization. Importantly, each subset of differentially expressed genes was linked to poor-prognosis in metastasis-free survival when analyzed in the KM plotter breast cancer clinical database (Fig. 5g). On the other hand, ECM genes specifically down-regulated by hysteretic EMT (FC > 1.95) is linked to good prognosis while MaSC-related genes down-regulated in hysteretic EMT did not show prognosis power. These results suggested a pro-metastatic gene expression program exclusively acquired by hysteretic EMT.

**Discussion**

EMT has long been linked to cancer progression and metastasis. However, there are still ongoing debates regarding its functional relevance in metastasis as different conclusions were drawn based on different model systems used. In our current study, we characterize two types of EMT dynamics (hysteretic and non-hysteretic) that notably influence the metastatic ability of the cancer cells, revealing an additional aspect to consider when studying EMT in cancer metastasis.

Previous computational studies have reported multistability of EMT controlled by the Snail/miR-34 and Zeb/miR-200s feedback loops. In addition, TGF-β has been shown to induce a bistable EMT in MCF10A cells. While Tian et al. suggested that the miR-34/SNAI1 and miR-200/ZEB1 loops function as bistable switches, Lu et al. suggested that the multistability predictions are due to the miR-200/ZEB1 axis, with the miR-34/SNAI1 axis functioning as a noise-buffer integrator of the system. Using CRISPR/Cas9-based manipulation of Zeb1 binding and repression of miR-200s/miR-141 promoter activity, we identified the tightly balanced miR-200s/Zeb1 feedback loop as the key hysteresis controller of EMT. This is in agreement with previous experimental and computational studies suggesting the Zeb/miR-200s axis as the key regulatory loop in EMT induction.

Additionally, despite the reciprocal regulation of miR-200s and Snail, our short-pulse TGF-β treatment data suggests Zeb1 and miR-200s as the main hysteresis controllers. However, we cannot rule out an additive or enhancing effect of latter players, such as Snail1, in enforcing the phenotypic state. In addition, other cell types may have higher dependency on Snail1, instead of Zeb1, depending on the cellular context. Moreover, we found that not all cellular systems exhibit hysteretic EMT dynamics, suggesting that these cell lines may have a disrupted equilibrium of the miR-200s/ZEBs feedback loop. For instance, mutations and epigenetic alterations on the promoters of the critical players, or the status of interconnected pathways, such as p53-dependent regulation of miR-200s, could disrupt the miR-200s/ZEBs equilibrium. Therefore, both EMT dynamics (hysteretic and non-hysteretic) exists in nature and are likely to depend on the cellular context and cell of origin.

The EMT dynamics might have important implications in physiological settings. An important finding from our study is the high sensitivity and memory of a hysteretic EMT: a short transient (5 min) exposure of picomolar quantities of TGF-β is sufficient to dictate the phenotypic EMT state of the cells for days, and is sufficient to increase metastasis. However, the absence of hysteresis reduces transition speed and steady-state resilience, and requires longer duration of TGF-β to induce and maintain EMT. Therefore, for tumor cells capable of undergoing hysteretic EMT, a short duration of exposure to TGF-β produced by tumor stromal cells, such as carcinoma associated fibroblasts (CAFs) or platelets, during invasion and dissemination may be sufficient to commit the disseminated tumor cells (DTCs) to EMT, and facilitate extravasation and early seeding of cancer cells at distant organs to promote metastasis formation. Hysteretic EMT therefore enables the transition to mesenchymal-like state without the need for long exposure of TGF-β, which have been shown to restrict cellular plasticity and induce cell differentiation as well as tumor suppression. As cellular plasticity is considered as a core condition for tumor progression and metastasis, hysteretic EMT may provide the necessary flexibility for cancer cells and avoid extreme phenotypes while subtle change in the miR-200-Zeb double negative feedback loop resulted in a more rigid non-hysteretic system.

Previous studies have reported the existence of distinct EMT programs depending on the specific EMT-inducing transcription factors and the cellular context. In our study, although both types of transition (hysteresis or non-hysteresis) reached the same degree of mesenchymal marker expression, hysteretic EMT cells expressed different subsets of genes related to metastasis and poor clinical outcome. This suggests the existence of distinct EMT programs and the critical role of the dynamics in influencing the
Fig. 5 Hysterectomy during EMT increases the metastatic colonization ability of EpRAS cells. **a** Quantification of invading cells in Matrigel transwell invasion assays after 24 h of seeding 100,000 EpRAS cells with or without 100 pM TGF-β treatment. *n = 3* biological replicates; data represents mean±SEM. **b** Quantification of mammosphere formation of 5,000 EpRAS cells with or without 100 pM TGF-β treatment. *n = 4* biological replicates; data represents mean±SEM. **c, d** Bioluminescence imaging (BLI) quantification (c) and representative images (d) of the metastatic growth of the EpRAS wild type and mutant cells in the lungs after tail vein injection of 20,000 cells in Ncr-nu/nu mice (*n = 6* mice). EpRAS cells were treated with the indicated concentration of TGF-β for 72 h (continuous) or 5 min followed by 72 h withdrawal (transient) prior to injection. Data represents mean±SEM. **e** Confocal microscopy imaging of CDH1 staining of lung metastatic tumor tissue. Wild type and mutant EpRAS cells were injected at the indicated conditions. Lung metastasis sample collection was done at the indicated time points after tail vein injection. Scale bar: 25 μm. **f** GSEA demonstrating the enrichment of the gene sets from the MSigDB related to mammary stem cells (Lim_MaSC_M2573) and ECM (Naba_ECM-GLYCOLPROTEINS_M3008) in the ranked gene list of TGF-β treated vs. control conditions in wild type or mutant EpRAS cells. NES, normalized enrichment score. **g** Heatmap of differentially expressed genes in Lim_MaSC (left) and Naba_ECM-GLYCOLPROTEINS datasets (right); color legend represents Log2 fold change (FC). Genes highlighted are genes with a >1.95 fold change (FC) during EMT in wild type but are not significantly changed in during EMT in mutant EpRAS cells. Kaplan-Meier distant metastasis free survival (DMFS) curves of breast cancer patients in the composite KM plotter breast cancer clinical database with higher or lower than median expression levels of the indicated gene sets were shown in the right side of the heatmap. *p < 0.05, **p < 0.01, ***p < 0.005* by two-tailed Student’s t-test in **a–c**, P-value by log-rank tests in **f**.
downstream cascade of EMT-associated genes. In fact, it has been previously reported that the particulars of the timing of transition and the sequence of the EMT/MET events are essential for acquiring the pluripotent state, in normal somatic cells. Indeed, EMT program is subjected to a very complex regulatory cascade involving the self-renewal (stemness) activity of DTCs to initiate metastasis. In particular, genes such as periostin (POSTN), which is differentially upregulated with hysteresis (Fig. 5g) has been reported to be critical for lung metastasis and stemness. The increase of metastasis by hysteresis may be due to the combination of higher sensitivity and longer persistence of EMT, as well as the subset of pro-metastatic and pro-metastatic genes specifically enhanced by hysteretic EMT. In addition, the reduced basal TGF-β level in non-hysteretic mutant cells may also contribute to their inability to respond to TGF-β induced EMT with increased metastatic potential. Consistently with our experimental observation in animal models, the subsets of genes specifically enhanced by hysteretic EMT correlate with poor prognosis. Taken together, our study reveals how different dynamics of EMT have different functional metastatic consequences and clinical prognosis outcomes.

Methods

Animal studies and bioluminescence analysis. All procedures involving mice and experimental protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of Princeton University. For limiting dilution assays to test tumor initiating cell (TIC) activity, we performed orthotopic mammary tumor injection of EpRAS in serial dilution numbers into the mammary fat pad (MFP) of female Balb/c mice. Six glands were used for each experimental group and the primary tumors were monitored weekly by palpation. Tumor monitoring and measurement were performed by trained technicians in a blinded fashion. Tumors were considered established when they became palpable for 2 consecutive weeks. ELDA (Extreme limiting dilution analysis) software was used to calculate the frequency of TICs with 95% of confidence. For lung metastasis colonization studies, the number of F- luciferase labeled EpRAS cells was injected into the lateral tail vein of female athymic Ncr−nu/nu mice. Development of metastases was monitored by bioluminescent imaging (BLI) following retro-orbital injection of 75 mg/kg β-luciferin. Randomization among litters was performed before injection, and animals were of similar age (6–8 weeks). No statistical method was used to predetermine the number of each gene of interest. BLI was normalized by the expression of mouse GAPDH or HMBS for mRNA, or RNU5B and SnoRNA-142 for miRNA, in each sample. The primers used for mRNA expression analyses are listed in the Supplementary Table 1.

Cell lines, culture conditions and treatments. Cell lines used in this study, including NMuMG (mouse mammary epithelial cell line), HMLE and MCF10A (human mammary epithelial cell lines), EpRAS and 4T1 (mouse mammary tumor cell lines), breast cancer cell lines R-5, R-MCF, TGF-β4 and BT474, were cultured using the standard conditions according the American Type Culture Collection (ATCC) instructions. All cell lines were verified negative for mycoplasma contamination by monthly PCR analysis. No cell lines used here appear in the database of commonly misidentified cell lines (ICLAC). All cell lines were validated with STR analysis and compared to NCBI repository data. GFP−/−luc labeled EpRAS cells were transduced with a lentivector expressing both GFP and firefly luciferase proteins. For EMT induction assays, recombinant TGF-β1 (R&D Systems) was diluted in PBS and added to cultured cells at the indicated concentration. Different treatment regimens were applied at the indicated concentration for each experiment: Continuous treatment lasted for 72 h. Transient (pulse) treatments lasted for the indicated period of time, followed by five consecutive washes with PBS and addition of TGEFRI inhibitor (EMB Millipore, 616452) to the culture media at a final concentration of 200 nM. For EMT reversion experiments, cells were treated for 72 h, and then TGF-β withdrawn as shown in the transient treatments. For paracrine effect experiments, GFP−/−luc NMuMG or EpRAS cells were cultured in 6-well plates (2 × 10^6 cells/well) and treated with 100 pM TGF-β for 24 h, washed five times with PBS, and overlaid with the unbleached and non-treated corresponding cell line for 72 h. For mammosphere assays, 5000 cells were plated in ultralow attachment plates (Corning) with the standard sphere media. The number of spheres were counted 6 days later.

Molecular cloning and CRISPR/Cas9 mediated genome editing. The mouse Zeb1 gene overexpression construct was generated using the pLEX-MCS-Puro lentiviral vector. cDNA was introduced into pLEX using the Spel and AgeI cutting sites. PCR primers used were: FW_Spel_Zeb1 (AGTCACTAGTCTACGACGAATGATCCAAC) and Rev_AgeI_Zeb1 (AGTCACGCGTCACTCATAACAGAAGGCTGTC). The Cdh1-EGFP reporter construct contains the −375/−135 CDH1 promoter inserted into the pEGFP-N1 plasmid using the Asel and BgIl1 sites. Mouse Cdna was introduced into pLEX using the Spel and AgeI sites. Deletion of the Z-box-2 Zeb1-binding site (−354/−360) on the mir-200/mir-141 promoter was achieved using the CRISPR-Cas9 vector system pLentiCRisp-v2. Luciferase (luc) reporter plasmids (pDNA oligo pairs: gRNA 5′-CACCCGGCTACGGCGCGCTGTG-3′ and reverse complement 5′-AAACCGCAACAGACCCCGTGCACC-3′) were cloned into the pLentiCRisp-v2. 48 h after transfection with the CRISPR-Cas9 construct, GFP-positive cells are sorted by FACS, seeded as single cells, and expanded into clonal populations. Clones with successful deletion of the Z-box-2 binding site was identified and confirmed by sequencing. All experiments where performed using wild type and mutant clonal populations except for Fig. 1 and Supplementary Fig. 1, in which experiments were done using the parental cell lines.

Viral production and transduction. Lentiviral plasmids were transfected into HEK293T cells together with the envelope plasmid (VSVG) and gag-pol plasmid (pCMV-dR8.91) following the standard lentiviral packaging protocol to generate lentiviral particles. Cells were transfected in culture and selected for the corresponding antibiotic resistance.

RNA isolation and quantitative real-time PCR. RNA from cell lines was isolated using a mirVana miRNA isolation kit (Ambion) or RNeasy mini kit (Qiagen). mRNA quantification was performed using the Superscript III First-strand kit (Invitrogen) for cDNA synthesis and the Power SYBR™ green PCR master mix (Applied Biosystems) for qPCR. miRNA expression was determined from serial dilutions of cDNA for each gene of interest. Values were normalized to mouse GAPDH or HMBS for mRNA, or RNU5B and SnoRNA-142 for miRNA, in each sample. The primers used for mRNA expression analyses are listed in the Supplementary Table 1.

Western blot analysis. SDS lysis buffer (0.5 mM Tris-HCl, 50 mM BME, 2% SDS, 0.1% Bromophenol blue, 10% glycerol) was used to collect protein from cells. Samples were heat denatured. Protein was equally loaded, separated on a 10% SDS-polyacrylamide gel, transferred onto a polyvinylidene fluoride (PVDF) membrane and blocked with 5% milk. Primary antibodies for immunoblotting included anti-pSMAD2 (1:1000, Cell Signaling, 12492, rabbit), anti-Vimentin (1:5000, BD Biosciences, 550513), and anti-CDH1 (1:1000, BD Biosciences, 610181), anti-CDH2 (1:2000, BD Biosciences, 610920), anti-ZEB1 (1:3000, BD Biosciences, A301-922A), anti-Vimentin (1:5000, BD Biosciences, 550513), and anti-β-Actin (1:5000, Abcam, ab8227) for loading control. Membranes were incubated with horseradish peroxidase (HRP)-conjugated anti-mouse secondary antibody (1:5000, GE Healthcare) or anti-rabbit secondary antibody (1:5000, GE Healthcare) for 1 h, after which chemiluminescent signals were detected using ECL substrate (GE Healthcare).

Immunofluorescence analysis and imaging. Cells were cultured on untreated coverslips in 6-well plates (2 × 10^4 cells/well) and treated as indicated. Coverslips were fixed for 30 min in methanol at −20 °C, washed with acetone, and then 5 times with PBS. Samples were blocked and permeabilized for 30 min in blocking buffer (5% normal goat serum, 3% Triton-X100 in PBS). Cells were incubated with anti-CDH1 antibody (BD Biosciences, 610181); diluted 1:100 in blocking buffer) for 1 h at RT. Secondary antibodies (BD Biosciences, 1:500) were incubated for 1 h at RT. Coverslips were mounted in DAPI mounting media (Vector Labs). Images were obtained using the Zeiss Axiovert 200 microscope with a 10x objective and the AxioVision software version 4.6.3 SP1.

Histology of mouse lung tissues. For quantification of metastatic lesions, mouse lungs were isolated, washed briefly in PBS, fixed in Bouin’s fixative (Sigma) overnight at 4°C, and stored in 70% ethanol before counting lung nodules. For histological analysis, lungs were fixed in 10% formalin overnight at 4°C, dehydrated, and embedded in paraffin (Tissue Tek Embedding Station). 3μm sections were cut on a Leica RM2235 rotary microtome. For antigen retrieval, deparaffinized slides were immersed in R-buffer A (Electron Microscopy Services) and boiled in a microwave for 20 min. Samples were blocked and permeabilized for 30 min in blocking buffer (5% normal goat serum, 0.3% Triton-X100 in PBS).
followed by primary antibody incubation overnight at 4 °C using anti-CDH1 (1:100, BD Biosciences, 610181). Secondary antibody (1:500, BD Biosciences) was incubated for 1 h at RT. All sections were analyzed using a Nikon A1 confocal microscope and Zeiss fluorescence microscope.

**Flow cytometry.** Cultured cells were lifted using enzyme-free cell dissociation buffer (Gibco), resuspended in FACS buffer (PBS supplemented with 5% newborn calf serum) and filtered through 100 μm nylon cell strainers. Samples were fixed in 4% formaldehyde for 10 min at 4 °C and permeabilized in ice cold methanol for 10 min; this fixation/permeabilization step is critical for the cell population distribution analysis. This was followed by staining with anti-CDH1-alexa488 antibody (1:200, Cell Signaling, 3199) for 30 min. Finally, cells were analyzed on a FACSort instrument (BD Biosciences).

**Transwell invasion assay.** Invasion assays were performed as previously described17. Briefly, inserts containing 8 μm pores (Costar) were coated with 50 μl growth-factor-reduced Matrigel (1 mg/ml, Corning) and allowed to solidify overnight at 37 °C. The following day, cells were trypsinized, washed in PBS, and resuspended in 10% calf serum. 106 cells were loaded on the insert. Inserts were then placed in wells with serum-containing media. 24 h post-seeding, the cells that had invaded into the wells were trypsinized, pelleted via centrifugation, resuspended in 100 μl media, and counted on a hemocytometer.

**Microarray analysis.** Wild type and mutant EpRAS cells were treated with 100 pM of TGF-β. Control cells were treated with the corresponding volume of PBS. After 3 days of continuous treatment, total RNA was prepared from cells using the RNeasy mini kit (Qiagen). The expression of mRNA in mouse cell lines was determined with the Agilent Mouse GEv1 8 × 60 K Microarray (G4852A). The mRNA microarray analyses were performed using a two color system. Briefly, the RNA samples and universal mouse reference RNA (Agilent 740100) were labeled with CTP-cy5 and CTP-cy3, respectively, using the Agilent Quick Amp Labeling Kit. Labeled testing and reference RNA samples were mixed in equal proportions, and hybridized to the arrays as described above. After hybridization, the mRNA arrays were scanned with an Agilent G2565BA scanner and raw data were extracted using Agilent Feature Extraction software (v10.7). Data were analyzed using the GeneSpring GX software (Agilent). The expression value of mRNA array refers to the Log2(Cy5/Cy3) ratio.

**Gene set enrichment analysis (GSEA).** Normalized microarray Log2 ratio expression data generated from EpRAS cells were rank-ordered by differential expression across cell populations using a fold change metric. Multiplicities of probes for the same gene were collapsed into one value by the highest probe reading when there were fewer than 3 probes match, and median when there were 3 or more probes matches. Interrogated signatures from the MSigDB v5.1 release include enrichment results from 1000 random permutations to obtain p-value, q-value, and median enrichment score from 1000 random permutations to obtain p-value, q-value, and median enrichment score (NES).

**Statistical analysis.** Results are presented as mean ± standard error of the mean (SEM), as indicated in figure legends. BLI signals were analyzed by nonparametric Mann–Whitney test. All other comparisons were analyzed by unpaired, two-sided, independent Student’s t-test without equal variance assumption, unless otherwise described in figure legends. Asterisks denote p-value significance: *p < 0.05; **p < 0.01; ***p < 0.001. Non-parametric datasets were evaluated using the Mann–Whitney U test. For metastasis-free survival analysis, Kaplan–Meier plots and significance with P log-rank test were used. All of the experiments with images (BLI, FACS, immunofluorescence, western blot) were repeated >3 times and representative images are shown.

**Code availability.** All computer code are scripts in Python or Mathematica. The scripts implement methods are described in the Supplementary mathematical analysis (Supplementary Tables 2-20) and are available from the corresponding authors upon request.

**Data availability**

All microarray data generated in this study have been deposited at the NCBI Gene Expression Omnibus with the accession code GSE106533 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE106533). Other gene sets used for GSEA analysis are found in the MSigDB database v5.1 release under the code: M5930, M2573, and M3008. The KM plotter breast cancer dataset9 is obtained from http://kmplot.com/analysis. All other data supporting the findings of this study are available from the corresponding authors upon request. A Reporting Summary for this Article is available as a Supplementary Information file.

**References**

1. Nieto, M. A., Huang, R. Y., Jackson, R. A. & Thiery, J. P. Emt: 2016. Cell 166, 21–45 (2016).
2. Yang, J. & Weinberg, R. A. Epithelial-mesenchymal transition: at the crossovers of development and tumor metastasis. Dev. Cell 14, 818–829 (2008).
3. Nieto, M. A. Epithelial plasticity: a common theme in embryonic and cancer cells. Science 342, 1234850 (2013).
4. Tsai, J. H. & Yang, J. Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev. 27, 2192–2206 (2013).
5. Ocana, O. H. et al. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 22, 709–724 (2012).
6. Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704–715 (2008).
7. Kudo-Saito, C., Shirako, H., Takeuchi, T. & Kawakami, Y. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 15, 195–206 (2009).
8. Fischer, K. R. et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527, 472–476 (2015).
9. Zheng, X. et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527, 525–530 (2015).
10. Singh, A. & Setlur, J., EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29, 4741–4751 (2010).
11. Cellia-Terrassa, T. et al. Epithelial-mesenchymal transition can suppress major attributes of human epithelial-tumor-initiating cells. J. Clin. Invest. 122, 1849–1868 (2012).
12. Grelet, S., Mchane, A., Geslain, R. & Howe, P. H. Pleiotropic roles of non-coding RNAs in TGF-beta-mediated epithelial-mesenchymal transition and their functions in tumor progression. Cancers 9, E75 (2017).
13. Peinado, H., Olmeda, D. & Cano, A. Snail and Zeb and BHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat. Rev. Cancer 7, 415–428 (2007).
14. Shrikahara, T., Saitoh, M. & Miyazono, K. Differential regulation of epithelial and mesenchymal markers by deltaEF1 proteins in epithelial mesenchymal transition induced by TGF-beta. Mol. Biol. Cell 18, 3533–3544 (2007).
15. Bracken, C. P. et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res. 68, 7846–7854 (2008).
16. Burk, U. et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 9, 582–589 (2008).
17. Korpal, M., Lee, E. S., Hu, G. & Kang, Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J. Biol. Chem. 283, 14910–14914 (2008).
18. Gregory, P. A. et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell. Biol. 10, 593–601 (2008).
19. Park, S. M., Gaur, A. B., Lengyl, E. & Peter, M. E. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 22, 894–907 (2008).
20. Gregory, P. A. et al. An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol. Biol. Cell 22, 1686–1691 (2011).
21. Jolly, M. K. et al. Implications of the hybrid epithelial/mesenchymal phenotype in metastasis. Front. Oncol. 5, 155 (2015).
22. Lu, M., Jolly, M. K., Levine, H., Onuchic, J. N. & Ben-Jacob, E. MicroRNA-based regulation of epithelial-hybrid-mesenchymal fate determination. Proc. Natl. Acad. Sci. USA 110, 18144–18149 (2013).
23. Tian, X. J., Zhang, H. & Xing, J. Coupled reversible and irreversible bistable switches underlying TGFbeta-induced epithelial to mesenchymal transition. Biophys. J. 105, 1079–1089 (2013).
24. Zhang, J. et al. TGF-beta-induced epithelial-to-mesenchymal transition proceeds through stepwise activation of multiple feedback loops. Sci. Signal. 7, ra91 (2014).
25. Jolly, M. K. et al. Coupling the modules of EMT and stemness: a tunable ‘stemness window’ model. Oncotarget 6, 25161–25174 (2015).
26. Perdigao-Henriques, R. et al. miR-200 promotes the mesenchymal to epithelial transition by suppressing multiple members of the Zeb2 and Snail1 transcriptional repressor complexes. Oncogene 35, 158–172 (2016).
27. Ferrell, J. E. Jr. Self-perpetuating states in signal transduction: positive feedback, double-negative feedback and bistability. Curr. Opin. Cell Biol. 14, 140–148 (2002).

28. Tyson, J. J., Chen, K. C. & Novak, B. Sniffers, buzzers, toggles and blinkers: dynamics of regulatory and signaling pathways in the cell. Curr. Opin. Cell Biol. 15, 221–231 (2003).

29. Garcia de Herreros, A. & Baulida, J. Cooperation, amplification, and feed-back in epithelial-mesenchymal transition. Biochim. Biophys. Acta 1825, 223–228 (2012).

30. Valcourt, U., Kowanetz, M., Niimi, H., Heldin, C. H. & Moustakas, A. TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol. Biol. Cell 16, 1987–2002 (2005).

31. Mani, S. A. et al. Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc. Natl Acad. Sci. USA 104, 10069–10074 (2007).

32. Rabitz, H. & Alis, O. F. General foundations of high-dimensional model representations. J. Math. Chem. 25, 197–233 (1999).

33. Sobol, I. M. Global sensitivity indices for nonlinear mathematical models and their Monte Carlo estimates. Math. Comput. Simul. 55, 271–280 (2001).

34. Malanchi, I. et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 481, 85–89 (2011).

35. Oskarsson, T., Batlle, E. & Massague, J. Metastatic stem cells: sources, niches, and vital pathways. Cell. Stem. Cell. 14, 306–321 (2014).

36. Gyorffy, B. et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res. Treat. 123, 725–731 (2010).

37. Aiello, N. M. et al. Upholding a role for EMT in pancreatic cancer metastasis. Nature 547, E7–E8 (2017).

38. Ye, X. et al. Upholding a role for EMT in breast cancer metastasis. Nature 547, E1–E2 (2017).

39. Chang, C. I. et al. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat. Cell Biol. 13, 317–323 (2011).

40. David, C. J. et al. TGF-beta tumor suppression through a lethal EMT. Cell 164, 1015–1030 (2016).

41. Juuti-Uusitalo, K. M., Kaukinen, K., Maki, M., Tuimala, J. & Kainulainen, H. Gene expression in TGFbeta-induced epithelial cell differentiation in a three-dimensional intestinal epithelial cell differentiation model. BMC Genom. 7, 279 (2006).

42. Celia-Terrassa, T. & Kang, Y. Distinctive properties of metastasis-initiating cells. Genes Dev. 30, 892–908 (2016).

43. Krebs, A. M. et al. The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat. Cell Biol. 19, 518–529 (2017).

44. Beerling, E. et al. Plasticity between epithelial and mesenchymal states unlinks EMT from metastasis-enhancing stem cell capacity. Cell Rep. 14, 2281–2288 (2016).

45. Taube, J. H. et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc. Natl Acad. Sci. USA 107, 15449–15454 (2010).

46. Ye, X. et al. Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. Nature 525, 256–260 (2015).

47. Liu, X. et al. Sequential introduction of reprogramming factors reveals a time-sensitive requirement for individual factors and a sequential EMT–MET mechanism for optimal reprogramming. Nat. Cell Biol. 15, 829–838 (2013).

48. Donut, G. et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 17, 1253–1270 (2003).

49. Said, N. A., Gould, C. M., Lackovic, K., Simpson, K. J. & Williams, E. D. Whole-genome multiparametric screening to identify modulators of epithelial-to-mesenchymal transition. Assay. Drug Dev. Technol. 12, 385–394 (2014).

50. Lim, E. et al. Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. Breast Cancer Res. 12, R21 (2010).

Acknowledgements
We thank M. Singh (Princeton University) for helpful suggestions and critical reading of the manuscript. This work was supported by a Susan G. Komen Fellowship to T.C.-T. (PDF15332075), NIH-NIDCR R01 DE02430 to C.B., and grants from the Breast Cancer Research Foundation, Department of Defense (BC123187), and the National Institutes of Health (RO1CA141062) to Y.K. and R01 CA198280-01. E.D.W. was supported by funding from the Australian Government Department of Health, Queensland Government National and the Movember Foundation and the Prostate Cancer Foundation of Australia through a Movember Revolutionary Team Award. This research was also supported by the Genomic Editing and Flow Cytometry Shared Resources of the Cancer Institute of New Jersey (P30CA072720).

Author contributions
T.C.-T., B.E. and Y.K. designed experiments. C.B. designed the computational and mathematical modeling. C.B., H.R., and D.K. performed computational analysis and provided advice. T.C.-T., D.L., B.E., X.H., Y.W., A.B., N.A., and W.L. performed the experiments. J.Z. performed dataset analysis. E.W. shared resources and advice. T.C.-T., C.B., R.E., and Y.K. wrote the manuscript. All authors discussed the results and commented on the manuscript.

Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-018-07538-7.

Competing interests: The authors declare no competing interests.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.